Spebrutinib

Drug Profile

Spebrutinib

Alternative Names: AVL-292; CC-292

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Avila Therapeutics
  • Developer Celgene Corporation
  • Class Acrylamides; Aniline compounds; Antineoplastics; Antirheumatics; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Phase I Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
  • No development reported Cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(In volunteers) in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, Second-line therapy or greater) in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Monotherapy, Second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top